Dr. Bhat is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-3196Fax+1 614-293-4812
Summary
- Dr. Seema A. Bhat is an Oncologist in Columbus, OH and is affiliated with multiple hospitals in the area, including James Cancer Hospital and Solove Research Institute and Ohio State University Wexner Medical Center. She received her medical degree from Government Medical College of Jammu and Kashmir and has been in practice for 19 years. She also speaks multiple languages, including Kashmiri, Urdu and Hindi. She specializes in hematologic/Medical oncology and is experienced in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, cold agglutinin disease, Autoimmune hemolytic anemia, Lymphomas and related disorders.
Education & Training
- University at BuffaloFellowship, Hematology and Medical Oncology, 2008 - 2011
- University at BuffaloResidency, Internal Medicine, 2004 - 2008
- Government Medical College of Jammu and KashmireClass of 1999
Certifications & Licensure
- OH State Medical License 2018 - 2025
- NY State Medical License 2011 - 2020
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia Start of enrollment: 2012 Apr 01
- First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Start of enrollment: 2020 Mar 24
Publications & Presentations
PubMed
- 1 citationsLP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia.Janani Ravikrishnan, Daisy Y Diaz-Rohena, Elizabeth Muhowski, Xiaokui Mo, Tzung-Huei Lai
Haematologica. 2025-01-01 - Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia.Evgeny Arons, Chin-Hsien Tai, Joshi Suraj, Yuelin Liu, Chi-Ping Day
Blood. 2024-12-24 - 1 citationsAtrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.John Alan Gambril, Sanam M Ghazi, Stephen Sansoterra, Mussammat Ferdousi, Onaopepo Kola-Kehinde
Leukemia. 2024-10-01
Abstracts/Posters
- Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK MutationsSeema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLLSeema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected CytotoxicitySeema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
- Novel Therapies and Their Impact on Treatment Pathways for Chronic Lymphocytic LeukemiaJanuary 13th, 2025
Committees
- Chairperson, P&T Comittee Roswell Park Comphrensive Cancer center 2014 - 2017
Professional Memberships
- Member
- Member
- Member
Other Languages
- Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: